Information Provided By:
Fly News Breaks for November 21, 2019
GLYC
Nov 21, 2019 | 13:57 EDT
Roth Capital analyst Zegbeh Jallah lowered her price target for GlycoMimetics to $9 from $12 after the company shifted the timeline regarding the readout of top-line clinical data for the ongoing Phase 3 study of uprolesela to sometime during 2021 from the end of 2020. Jallah, however, remains positive on the outlook of the program, and made no changes to the probability of success of uproleselan. Further, she remains bullish on GMI-1359, which she notes remains on track to readout during 2020. The analyst keeps a Buy rating on GlycoMimetics.
News For GLYC From the Last 2 Days
There are no results for your query GLYC
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.